LDL-C meta-analysis showing in (A) the overall effects of different statin types versus placebo and (B) stratified by statin treatment duration for 3-4 months and longer than 4 mon... by Solima Sabeel (9545738)

Subjects:

Overall analysis of randomized controlled trials. by Solima Sabeel (9545738)

Subjects:

Summary table showing analysis of randomized controlled trials stratified based on age groups. by Solima Sabeel (9545738)

Subjects:

Meta-analysis showing the overall effect of different statin types versus placebo for by Solima Sabeel (9545738)

Subjects:

Version 2 of the Cochrane risk-of-bias tool for randomized controlled trials. by Solima Sabeel (9545738)

Subjects:

Analysis of randomized controlled trials stratified based on treatment duration. by Solima Sabeel (9545738)

Subjects:

Funnel plots of studies included in the meta-analysis assessing by Solima Sabeel (9545738)

Subjects:

Summary of non-randomized studies. by Solima Sabeel (9545738)

Subjects:

PRISMA flow diagram of the systematic literature search process. by Solima Sabeel (9545738)

Subjects:

Newcastle-Ottawa scale. by Solima Sabeel (9545738)

Subjects:

The effect of HA digestion and HA replenishment alone or with CS on barrier function measured by TEER. by Charlotte J. van Ginkel (20790466)

“…In (B) and (C) each point represents a mean ± standard deviation. (B) Hyaluronidase treatment (n = 8) gradually increased TEER, this significantly differed from the untreated group (n = 8) and the PS treated group (n = 8) (p < 0,001). …”

Mean case duration before and after intervention (t-statistic = -3.35, p <i>< </i>0.001), indicating a statistically significant difference in means. by Mohammad Bakhtiari (11838264)

Dose-dependent reduction of lactate formation by Jurkat cells. by Samo Lešnik (21073880)

Summary of significant treatment × time effect. by Wensheng Xiao (16557866)

IL-10 levels in tumor lysates post-treatment. by Hedieh Zargaran (21410233)

Cytotoxicity (as of %Control) IC₅₀ value (mean ±SD in µM) of the tested compounds vs. Positive controls Cisplatin and doxorubicin against gastrointestinal and colorectal... by MohammedBashar Al-Qazzan (22439236)

Subjects:

Cytotoxicity (as of %Control) IC₅₀ value (mean ±SD in µM) of the tested compounds vs. positive controls Cisplatin and doxorubicin against other malignancy’ cell lines ad... by MohammedBashar Al-Qazzan (22439236)

Subjects:

Changes in connectivity of the mPFC among responders and non-responders. by Karel Joineau (21799908)

Subjects:

Data supporting this article. by Karel Joineau (21799908)

Subjects:

CONSORT diagram showing the flow of participants through each stage of the DOREPAR randomized trial for the main outcome (change of VAS). by Karel Joineau (21799908)

Subjects: